{"entity":{"id":"nct06725758","kind":"trial","name":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of ODM-212 in advanced solid tumours, run by Orion Corporation, Orion Pharma, now recruiting.","summary":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06725758 by Orion Corporation, Orion Pharma, with 315 participants planned, started 2023-10-26 and due to reach its primary completion in 2027-12-31. Interventions recorded: ODM-212.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06725758","url":"https://clinicaltrials.gov/study/NCT06725758"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06725758","phase":"1/2","setting":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","sponsor":"Orion Corporation, Orion Pharma","enrolled":315,"outcomes":[]},"route":"/trials/nct06725758/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}